key: cord-0785200-n4334ce5
authors: Basalely, Abby; Brathwaite, Kaye; Duong, Dien; Liu, Diane; Mazo, Alexandra; Xie, Yuping; Del Rio, Marcela; Goilav, Beatric; Hayde, Nicole; Kaskel, Frederick J.; Zolotnitskaya, Anna; Reidy, Kimberly J.
title: COVID-19 in Children With Kidney Disease: A Report of 2 Cases
date: 2020-11-21
journal: Kidney Med
DOI: 10.1016/j.xkme.2020.09.007
sha: 34fd922ee5d8257d67370def39ccaa26df09a40b
doc_id: 785200
cord_uid: n4334ce5

The presentation of the novel coronavirus disease 2019 (COVID-19) in children with kidney disease is largely unknown. We report on two children with kidney disease not on chronic immunosuppression who were hospitalized due to COVID-19. The first case is an infant with end stage kidney disease (ESKD) secondary to bilateral cystic dysplastic kidneys and posterior urethral valves on peritoneal dialysis, with a history of prematurity previously requiring mechanical ventilation in the neonatal intensive care unit, who presented with fever, hypertension, and emesis. He had no respiratory symptoms and recovered with supportive care. His hypertension was managed well with amlodipine. The second case is a child with steroid sensitive nephrotic syndrome who presented with a relapse of nephrotic syndrome with concurrent peritonitis and streptococcal agalactiae sepsis. He was treated with antibiotics and prophylactic anticoagulation, and steroid therapy was initiated after 48 hours of antibiotics. Neither child required mechanical ventilation nor developed COVID-19 related multisystem inflammatory syndrome.

As of April 24 th 2020, the Montefiore-Einstein Hospital system admitted over 170 adults with End Stage Kidney Disease (ESKD) on dialysis and 70 kidney transplant recipients with COVID19 disease 1, 2 . In contrast, during the same time period, only 3 pediatric patients with preexisting kidney disease were admitted with COVID19 infection. Previous reports describe worse outcomes and more severe COVID19 disease in adult patients with chronic kidney disease (CKD), ESKD and transplant [3] [4] [5] [6] [7] , while early reports suggest mild illness in European children with CKD 8, 9 . In addition, atypical presentation of SARS-CoV-2 infection with predominant gastrointestinal symptoms have been reported in these populations 10 . As COVID19 presentation in children with kidney disease from the United States is not well described, we report on 2 children with kidney disease not on chronic immunosuppression admitted to our Children's Hospital due to COVID19 infection.

A Hispanic male infant with end-stage kidney disease (ESKD) secondary to bilateral cystic dysplastic kidneys and posterior urethral valves (PUV) on peritoneal dialysis (PD), presented to the emergency room with one day of lethargy and abdominal distension. He had no feeding difficulties, rhinorrhea, cough, shortness of breath, diarrhea, vomiting or sick contacts; however, in the week prior to admission, New York State "Stay at Home" orders were not yet in place. During his hospitalization, he developed persistent brownish emesis. Abdominal X-ray and ultrasound showed no small bowel obstruction. He received bowel rest, intravenous (IV) fluids and lansoprazole. Emesis improved after 2 days. Hypertension was controlled with amlodipine. He did not require supplemental oxygen. Patient was discharged home after 3 days and is thriving and tolerating feeds with normal blood pressures.

An elementary-school aged Hispanic male with steroid sensitive nephrotic syndrome presented with 2 days of subjective fever, non-bilious non-bloody emesis, anasarca, and right lower quadrant abdominal pain. The morning of presentation, the mother gave one dose of prednisolone at home for presumed relapse. Review of systems was notable for 2 weeks of cough and sick contacts (2 household members with cough and anosmia).

Past medical history was notable for presentation with steroid sensitive nephrotic syndrome at 3 years of age. He had infrequent relapses, most recently 3 months prior to presentation.

Vital signs on presentation were notable for T 38.5°C, BP 91/69 mmHg, HR 165 bpm, RR 22 rpm, SpO2 100% on RA. His weight was approximately 6kg above his estimated dry weight. On physical exam, he was ill appearing with pallor, poor peripheral perfusion, moderate ascites, and right lower quadrant abdominal tenderness and rebound.

RT PCR was positive. His initial laboratory evaluation demonstrated relapse of his nephrotic syndrome (Table 1) . Chest X-ray showed small patchy opacities in the right upper lung field and left lung base concerning for an early pneumonia.

Abdominal ultrasound showed mild to moderate complex ascites with septations.

Computerized tomography scan demonstrated ascites, small bilateral pleural effusions, and mild pulmonary interstitial edema. Blood cultures were positive for Streptococcus agalactiae.

He received IV fluid boluses and IV ceftriaxone and piperacillin-tazobactam due to concern for spontaneous bacterial peritonitis. He also received stress dose hydrocortisone and 25% Albumin (1gm/kg) with IV furosemide (1mg/kg/dose). Within 12 hours after admission, he developed oxygen desaturations to 80% and was placed on low flow oxygen with nasal cannula at 3 liters per minute. He was started on prophylactic enoxaparin due to concern for increased risk of thrombosis due to nephrotic syndrome and COVID19 infection. Remdesivir, which may accelerate recovery from advanced COVID-19, 11 was offered but declined. After 48 hours, the patient became afebrile and no longer required oxygen. He was started on prednisolone (2mg/kg/day) for his J o u r n a l P r e -p r o o f nephrotic syndrome and responded after 7 days. He received a total of 10 days of antibiotic treatment and was continued on 2 weeks of prophylactic enoxaparin therapy following discharge.

Because his nephrotic syndrome hae been sensitive to steroids, he presented with proteinuria when relapsing and subsequently proteinuria went away with a steroid treatment course. He was intially diagnosed 3 ½ years before the current presentation, and presented with urine protein:creatinine (UPC) ratio of 46mg/mg and completed into remission the following month with UPC ratio at 0.1mg/mg, within normal range. He was noted to have 3 relapses of NS, approximately 3 years, 2 ¼ years, and 2 years prior to the current presentation, all of which relapses were into remission with negative proteinuria.

Before this admission, his urine dipstick showed negative for protein. The UPC ratio at this admission was 18.7mg/mg then became negative before discharge. His urine dipstick remains negative for protein.

Here we report 2 Hispanic children with different pre-existing kidney diseases admitted with COVID-19 infection. The presentation, disease severity, and treatment were variable; however, none required mechanical ventilation nor experienced SARs-CoV-2 related multisystem inflammatory syndrome.

The first patient was an infant with ESKD secondary to PUV on PD presenting with fever, hypertension and gastrointestinal symptoms. Remarkably, despite his history of prematurity requiring substantial respiratory support at birth, he experienced no respiratory symptoms.

The second patient with nephrotic syndrome presented with relapse of his nephrotic syndrome, streptococcal agalactiae sepsis and peritonitis. Although rare, Streptococcal agalactiae has been reported as an infectious bacterium in nephrotic syndrome 12 . SARs-COV2 infection may have triggered relapse in this patient, as was recently reported in a Spanish study 9 . It is unclear if it contributed to his severity of illness. Secondary FSGS has been noted in high-risk phenotype ApoL1 adults with COVID-19 13 . However this patient's ApoL1 status was unknown, as genetic studies were not sent previously. High dose steroids were postponed until the patient was afebrile and had negative blood cultures for 48 hours, but the patient responded well to steroid therapy. The patient also had an elevated d-dimer and was treated with prophylactic enoxaparin. Hypercoagulability is associated with both nephrotic syndrome and COVID19 infection, and it is unclear if they synergistically increase risk for thrombosis [14] [15] [16] .

Early reports have indicated mild COVID19 illness in European children with kidney disease 17, 18 . However, increased morbidity and mortality has been reported in Black and Hispanic adults 19 . One of the two children reported here with COVID19 infection required intensive care with oxygen support. Additional studies of COVID19 infection in children with kidney disease are needed. 

Covid-19 and Kidney Transplantation

Early Description of Coronavirus 2019 Disease in Kidney Transplant Recipients in New York

Management of Hemodialysis Patients with Suspected or Confirmed COVID-19 Infection: Perspective of Two Nephrologists in the United States

Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection

Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China

COVID-19: Clinical course and outcomes of 36 maintenance hemodialysis patients from a single center in Spain

A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection

The severity of COVID-19 in children on immunosuppressive medication. The Lancet Child & Adolescent Health

SARS-CoV-2 infection in Spanish children with chronic kidney pathologies

COVID-19 in Hemodialysis Patients: A Report of 5 Cases

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Group B streptococcal cellulitis in a child with steroidresponsive nephrotic syndrome

AKI and Collapsing Glomerulopathy Associated with COVID-19 and APOL-1 High-Risk Genotype

Serum D-dimer concentrations in nephrotic syndrome track with albuminuria, not estimated glomerular filtration rate

Risk factors of pulmonary thrombosis/embolism in nephrotic syndrome

Hematological findings and complications of COVID-19

A single-center, retrospective study of COVID-19 features in children: a descriptive investigation

Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units

COVID-19 and Racial/Ethnic Disparities